Amphastar Pharmaceuticals AMPH Noncash Operating Lease Right Of Use Asset
Noncash Operating Lease Right Of Use Asset at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept amph:NoncashOperatingLeaseRightOfUseAsset.
The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amphastar Pharmaceuticals's noncash operating lease right of use asset.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amphastar Pharmaceuticals's noncash operating lease right of use asset?
- Amphastar Pharmaceuticals (AMPH) reported noncash operating lease right of use asset of $30.71M in Q1 2026.
- How has Amphastar Pharmaceuticals's noncash operating lease right of use asset changed year-over-year?
- Amphastar Pharmaceuticals's noncash operating lease right of use asset increased by 5794.2% year-over-year, from $521K to $30.71M.
- What does noncash operating lease right of use asset mean?
- This metric represents the non-cash value of new right-of-use assets recognized on the balance sheet due to the commencement of new operating leases. It is a non-cash accounting entry that reflects the company's commitment to future lease payments without an immediate impact on cash flow. Investors monitor this to understand the scale of new lease obligations entered into during the period.